Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Prilosec OTC Formulation Targeted In Mylan Labs Suit

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Mylan Laboratories' lawsuit against Procter & Gamble over the formulation of Prilosec OTC is the most recent in a string of challenges for the over-the-counter heartburn medication

You may also be interested in...



Mylan Seeks Halt Of “Misleading” Prilosec OTC Ad Claims In Suit

Mylan Labs requests preliminary and permanent injunctions against Procter & Gamble ad claims that Prilosec OTC and Rx Prilosec are the same drug in its complaint against the firm in Manhattan federal court

Mylan Seeks Halt Of “Misleading” Prilosec OTC Ad Claims In Suit

Mylan Labs requests preliminary and permanent injunctions against Procter & Gamble ad claims that Prilosec OTC and Rx Prilosec are the same drug in its complaint against the firm in Manhattan federal court

Mylan Seeks Halt Of “Misleading” Prilosec OTC Ad Claims In Suit

Mylan Labs requests preliminary and permanent injunctions against Procter & Gamble ad claims that Prilosec OTC and Rx Prilosec are the same drug in its complaint against the firm in Manhattan federal court

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

EU CHMP Opinions And MAA Updates

Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access

EU Group Facilitates Switching Multinational Trials To CTR

As New Tech Emerges For Early Research, FDA Chief Scientist Says Diversity Must Start In Preclinical Development

See All
UsernamePublicRestriction

Register

PS096329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By